Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI ® (sparsentan) in the treatment of focal ...

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure ...

Its distillery at 2700 Guinotte Ave. in Kansas City is only about 10 miles from the Kansas City Current’s Training Facility ...

DNA Numerovahti, which translates loosely to “number guardian” in Finnish, is available to consumer subscribers through DNA’s new DNA Huoleton Plus tier, where it is bundled alongside safe browsing ...